Related Experiment Video
Updated: Sep 14, 2025
A Comprehensive Procedure to Evaluate the In Vivo Performance of Cancer Nanomedicines
Published on: March 4, 2017
An overview of randomized phase III clinical trials of cancer nanomedicines
Micael N Melo1, Ricardo G Amaral2, Lucas R Melo de Andrade3
1Department of Medicine, Federal University of Sergipe, Lagarto, Sergipe 49400-000, Brazil.
Background:
Cancer therapy has undergone significant advances in recent decades attributed to personalized medicine and targeted drug delivery. Among the promising approaches, the use of nano-based delivery systems has become a relevant approach capable of improving treatment by releasing antineoplastic drugs at the target site, improving therapeutic efficacy, minimizing cytotoxicity in healthy tissues, and ultimately, reducing the intensity of adverse effects of chemotherapy. This study prospectively evaluated the impact of formulating anti-neoplastic drugs as nanomedicines on clinical response, overall survival, safety, and quality of life of cancer patients, based on the outcomes of randomized clinical trials.
Methods:
A literature review was carried out by systematically searching the PubMed/MEDical Literature Analysis and Retrieval System Online (MEDLINE), Excerpta Medica Database (EMBASE), and Latin American and Caribbean Health Sciences Literature (LILACS) databases for phase III clinical trials, comparing nanomedicines with conventional therapies for the treatment of various cancer types.
Results:
The nanomedicines analyzed were those that are approved and used in Brazil, considering the country's emerging market for advanced cancer treatments. From a total of 303 articles found, 26 articles were selected for systematic review. Studies showed that PEGylated l-asparaginase achieved a similar therapeutic effect to that of l-asparaginase, with fewer applications due to its longer half-life. Paclitaxel bound to albumin improved therapeutic efficacy as well as reduced infusion time and solvent-related toxicity of the conventional paclitaxel formulation. PEGylated liposomal doxorubicin showed better pharmacokinetics, reduced cardiotoxicity, and improved quality of life in cancer patients compared to that of free doxorubicin.
Conclusions:
This study reinforces the scientific evidence of the added value of nanomedicines to improve therapeutic efficacy and reduce toxicity in patients under chemotherapy.
Insights
Nanomedicines enhance cancer treatment by improving drug delivery and reducing side effects. This review of clinical trials confirms their value in increasing therapeutic efficacy and patient quality of life.
Area of Science:
- Oncology
- Nanotechnology
- Pharmacology
Background:
- Cancer therapy advances driven by personalized medicine and targeted drug delivery.
- Nano-based delivery systems improve antineoplastic drug efficacy and minimize toxicity.
- Nanomedicines offer potential for improved cancer treatment outcomes.
Purpose of the Study:
- Evaluate nanomedicines' impact on clinical response, survival, safety, and quality of life.
- Assess outcomes of randomized clinical trials comparing nanomedicines and conventional therapies.
- Provide evidence for the clinical value of nanomedicine in cancer care.
Main Methods:
- Systematic literature review of phase III clinical trials.
- Searched PubMed/MEDLINE, EMBASE, and LILACS databases.
- Included nanomedicines approved and used in Brazil.
Main Results:
- PEGylated l-asparaginase showed comparable efficacy with fewer doses.
- Albumin-bound paclitaxel improved efficacy and reduced toxicity.
- PEGylated liposomal doxorubicin demonstrated better pharmacokinetics and reduced cardiotoxicity.
Conclusions:
- Nanomedicines offer significant added value in cancer chemotherapy.
- Improved therapeutic efficacy and reduced toxicity are key benefits.
- Evidence supports nanomedicines for enhanced patient outcomes and quality of life.
Related Concept Videos
01:11Clinical Trials: Overview
01:16Clinical Trials
There are four phases in a clinical trial. A phase one...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:28Preclinical Development: Overview
01:26Drug Administration and Therapy Phases: Overview
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...